| Pulmonary arterial hypertension

Opsumit vs Tadliq

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.

Deep comparison between: Opsumit vs Tadliq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTadliq has a higher rate of injection site reactions vs Opsumit based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tadliq but not Opsumit, including UnitedHealthcare

Category

Opsumit

Tadliq

At A Glance

RouteOral

FrequencyDaily

ClassEndothelin receptor antagonist

RouteOral

FrequencyOnce daily

ClassPDE5 inhibitor

Indications

Pulmonary arterial hypertension

Pulmonary arterial hypertension

Dosing

Pulmonary arterial hypertension 10 mg once daily orally; doses higher than 10 mg once daily have not been studied in patients with PAH and are not recommended.

Pulmonary arterial hypertension 40 mg (10 mL) once daily with or without food; start at 20 mg (5 mL) once daily in mild-to-moderate renal or mild-to-moderate hepatic impairment, increasing to 40 mg based on tolerability; avoid in severe renal impairment and severe hepatic impairment; when initiating TADLIQ in patients on ritonavir for at least one week, start at 20 mg once daily and increase to 40 mg based on tolerability; when starting ritonavir in patients already on TADLIQ, stop TADLIQ at least 24 hours prior and resume at 20 mg once daily after at least one week.

Contraindications

Pregnancy (may cause fetal harm)
History of hypersensitivity reaction to macitentan or any component of the product

Concomitant use of any form of organic nitrate, either regularly or intermittently
Concomitant use of guanylate cyclase (GC) stimulators such as riociguat
Known serious hypersensitivity to tadalafil (TADLIQ, ADCIRCA, or CIALIS)

Drug Interactions

1149View drug interactions

1155View drug interactions

Adverse Reactions

Most common (>=3%) anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, urinary tract infection

Serious embryo-fetal toxicity, hepatotoxicity, fluid retention, decrease in hemoglobin

Postmarketing hypersensitivity reactions (angioedema, pruritus, rash), flushing, nasal congestion, liver aminotransferase elevations and liver injury, edema/fluid retention, symptomatic hypotension

Most common (>=9%) Headache, myalgia, nasopharyngitis, flushing, respiratory tract infection, pain in extremity, nausea, back pain, dyspepsia, nasal congestion

Serious Hypotension, visual loss, hearing loss, priapism

Postmarketing Serious cardiovascular events (myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, tachycardia), hypersensitivity reactions (urticaria, Stevens-Johnson syndrome, exfoliative dermatitis), migraine, seizure, transient global amnesia, visual field defect, retinal vein occlusion, retinal artery occlusion, NAION, sudden hearing decrease or loss, priapism

Pharmacology

Macitentan is an endothelin receptor antagonist that inhibits binding of ET-1 to both ETA and ETB receptors with high affinity and sustained occupancy in human pulmonary arterial smooth muscle cells; an active metabolite contributes approximately 40% of total pharmacologic activity.

PDE5 inhibitor; tadalafil selectively inhibits phosphodiesterase type 5, increasing cGMP concentrations in pulmonary vascular smooth muscle, resulting in relaxation and vasodilation of the pulmonary vascular bed in patients with pulmonary arterial hypertension.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Opsumit